Press Releases on September 17, 2018 - EIN Presswire - Press Release Distribution Service

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Tegsedi, inotersen, Amyloidosis, Date of authorisation: 06/07/2018, ...

Tegsedi is a medicine used to treat nerve damage caused by hereditary transthyretin amyloidosis (hATTR), a disease in which proteins called amyloids build up in tissues around the body including around the nerves. Tegsedi is used in adult patients in the …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Benlysta,belimumab, decision type: , therapeutic area: , PIP number: P/...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Temodal, temozolomide, Glioma;Glioblastoma, Date of authorisation: 26/01/...

The most common side effects with Temodal (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, constipation, loss of appetite, alopecia (hair loss), headache, fatigue (tiredness), convulsions (fits), rash, neutropenia or lymphopenia ( …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Temodal, temozolomide, Glioma;Glioblastoma, Date of authorisation: 26/01/...

The most common side effects with Temodal (seen in more than 1 patient in 10) are nausea (feeling sick), vomiting, constipation, loss of appetite, alopecia (hair loss), headache, fatigue (tiredness), convulsions (fits), rash, neutropenia or lymphopenia ( …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Dyslipidemias, Date of authorisation: 23/09/2015, ...

Primary hypercholesterolaemia and mixed dyslipidaemia Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Praluent, alirocumab, Dyslipidemias, Date of authorisation: 23/09/2015, ...

Primary hypercholesterolaemia and mixed dyslipidaemia Praluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Opinion/decision on a Paediatric investigation plan (PIP): (E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo[3.3.1.13,7]...

(E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo[3.3.1.13,7] decane 3,4-dicarboxy-3-hydroxybutanoate hydrate (ABT-126)

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, ...

Blitzima is indicated in adults for the following indications: Non-Hodgkin’s lymphoma (NHL) Blitzima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. Blitzima …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Lymphoma, Non-Hodgkin;Leukemia, Lymphocytic, ...

Blitzima is indicated in adults for the following indications: Non-Hodgkin’s lymphoma (NHL) Blitzima is indicated for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy. Blitzima …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Tafinlar,dabrafenib mesilate, decision type: , therapeutic area: , PIP ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop), clopidogrel, ...

Clopidogrel Zentiva has been compared with aspirin in a study called CAPRIE including around 19,000 patients who had recently had a heart attack or ischaemic stroke, or who had established peripheral arterial disease. The main measure of effectiveness was …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Clopidogrel Zentiva (previously Clopidogrel Winthrop), clopidogrel, ...

Clopidogrel Zentiva has been compared with aspirin in a study called CAPRIE including around 19,000 patients who had recently had a heart attack or ischaemic stroke, or who had established peripheral arterial disease. The main measure of effectiveness was …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Opinion/decision on a Paediatric investigation plan (PIP): Veyvondi,vonicog alfa, decision type: , therapeutic area: , PIP number: ...

For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Insulin lispro Sanofi, insulin lispro, Diabetes Mellitus, Date of ...

Insulin lispro Sanofi is given as an injection under the skin in the upper arm, thigh, buttock or belly. It can also be given with an infusion pump. In some circumstances, such as when blood acid levels are dangerously high (ketoacidosis), the medicine may …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Insulin lispro Sanofi, insulin lispro, Diabetes Mellitus, Date of ...

Insulin lispro Sanofi is given as an injection under the skin in the upper arm, thigh, buttock or belly. It can also be given with an infusion pump. In some circumstances, such as when blood acid levels are dangerously high (ketoacidosis), the medicine may …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Oprymea, pramipexole, Parkinson Disease, Date of authorisation: 12/09/...

Oprymea can only be obtained with a prescription. It is available as immediate-release tablets (0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg and 1.1 mg) and prolonged-release tablets (0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg). Immediate– …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Oprymea, pramipexole, Parkinson Disease, Date of authorisation: 12/09/...

Oprymea can only be obtained with a prescription. It is available as immediate-release tablets (0.088 mg, 0.18 mg, 0.35 mg, 0.7 mg and 1.1 mg) and prolonged-release tablets (0.26 mg, 0.52 mg, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg and 3.15 mg). Immediate– …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Levetiracetam Hospira, levetiracetam, Epilepsy, Date of authorisation: ...

Levetiracetam Hospira is an epilepsy medicine. It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Human medicines European public assessment report (EPAR): Levetiracetam Hospira, levetiracetam, Epilepsy, Date of authorisation: ...

Levetiracetam Hospira is an epilepsy medicine. It can be used on its own in patients from 16 years of age with newly diagnosed epilepsy, to treat partial-onset seizures (fits) with or without secondary generalisation. This is a type of epilepsy where too …

Distribution channels: Healthcare & Pharmaceuticals Industry

Published on September 17, 2018 - 12:26 GMT

Avivagen Announces Approval from TSX Venture Exchange for Extension of Warrants

OTTAWA, Sept. 17, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Company”), a life sciences innovation company with a series of patent protected products that support and optimize human and animal health, that it has …

Distribution channels: Banking, Finance & Investment Industry, Technology ...